872355-60-7

Basic information

• Product Name: METHYL 5-AMINO-6-IODOPICOLINATE
• Synonyms: METHYL 5-AMINO-6-IODOPICOLINATE;methyl 5-amino-6-iodopyridine-2-carboxylate;5-Amino-6-iodo-pyridine-2-carboxylic acid methyl ester;methyl5-amino-6-iodopicolinate(WX191808)
• CAS NO: 872355-60-7
• Molecular Formula: C₇H₇IN₂O₂
• Molecular Weight: 278.04715
• Mol File: 872355-60-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL 5-AMINO-6-IODOPICOLINATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-AMINO-6-IODOPICOLINATE(872355-60-7)
• EPA Substance Registry System: METHYL 5-AMINO-6-IODOPICOLINATE(872355-60-7)

Safety Data

• Hazardous Substances Data: 872355-60-7(Hazardous Substances Data)

Upstream product

• 67515-76-8 methyl 5-amino-2-pyridinecarboxylate 
• 24242-20-4 5-amino-pyridine-2-carboxylic acid 
• 55338-73-3 5-amino-2-cyanopyridine 

Downstream Products

• 872355-63-0 methyl 1H-pyrrolo[3,2-b]pyridine-5-carboxylate 
• 872355-64-1 1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid 

Relevant articles and documents

TRIAZINE DERIVATIVE HAVING EGFR INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF

Disclosed are a triazine derivative having EGFR inhibitory activity, a preparation method therefor and use thereof. In particular, disclosed are an EGFR inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, use thereof for preparing the EGFR inhibitor, and use thereof in preparing medicaments for treating and/or preventing cancers, tumors or metastatic diseases at least partially related to insertion, deletion or other mutation of EGFR exon 20, and in particular use thereof in preparing medicaments for treating and/or preventing hyperproliferative diseases and diseases inducing cell death disorders. The definition of each substituent of formula (I) is the same as that in the description.

Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma

Synthesis of a new series of diarylureas and amides having pyrrolo[3,2-b]pyridine scaffold is described. Their in vitro antiproliferative activity against human melanoma cell line A375 and HS 27 human fibroblast cell line was tested and the effect of subs

NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES

[Purpose] The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. [Solution] The present invention provides nitrogen-containing fused ring derivatives represented by the following general formula (I) which has a GnRH antagonistic activity, prodrugs, salts, pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A and B are independently aryl or heteroaryl; RA and RB are independently halogen, cyano, alkyl, alkylsulfonyl, -OW1, -SW1, -COW2, -NW3W4, -SO2NW3W4, aryl, etc.; RC is H or alkyl; E is oxygen atom, etc.; U is single bond or alkylene; and X is Y, -CO-Y, -SO2-Y -S-(alkylene)-Y, -O-(alkylene)-Y, -SO2-(alkylene)-Y, etc.; Y is Z or amino, etc.; and Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.

AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE

The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through an azacyclic linker to another cyclic moiety.